Value Partners led a $123m Series E round in Insilico Medicine.

Value Partners, a fund and asset management company, led a $123m Series E round in Insilico Medicine, a clinical-stage, AI-driven drug discovery company, with participation from Grand Leader and Prosperity7 Ventures. “We are extremely grateful for the continued support from our investors, both new and existing, who share our vision for the future of AI-driven drug discovery and healthcare. The oversubscribed completion of the Series E round is a milestone that not only accelerates the growth of our innovative pipeline and AI technologies but also underscores the industry’s recognition of our capabilities. We are committed to advancing transformative therapies and driving meaningful impact across the pharmaceutical landscape,” Alex Zhavoronkov, Insilico Medicine Founder and Co-CEO.